Stock RPGLIFE RPG LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials RPG Life Sciences Limited Bombay S.E.

Equities

RPGLIFE

INE105J01010

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:50 2024-05-03 am EDT 		5-day change 1st Jan Change
1,471 INR -2.00% Intraday chart for RPG Life Sciences Limited -6.14% +10.09%
May. 02 Transcript : RPG Life Sciences Limited, Q4 2024 Earnings Call, May 02, 2024
Apr. 30 RPG Life Sciences Limited Recommends Equity Dividend for the Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 6,315 4,099 2,808 6,407 9,269 11,585
Enterprise Value (EV) 1 6,856 4,460 2,920 6,024 8,709 10,752
P/E ratio 46.9 x 37.9 x 9.68 x 16 x 18 x 17.1 x
Yield 0.63% 0.97% 2.36% 1.86% 1.71% 1.71%
Capitalization / Revenue 1.84 x 1.24 x 0.75 x 1.65 x 2.11 x 2.26 x
EV / Revenue 1.99 x 1.35 x 0.78 x 1.55 x 1.98 x 2.1 x
EV / EBITDA 18.2 x 13.4 x 5.19 x 8.81 x 10.3 x 10.5 x
EV / FCF -77.5 x 20.5 x 10.7 x 16.4 x 39.3 x 35.7 x
FCF Yield -1.29% 4.89% 9.36% 6.1% 2.55% 2.8%
Price to Book 4.08 x 2.55 x 1.59 x 2.96 x 3.62 x 3.77 x
Nbr of stocks (in thousands) 16,539 16,539 16,539 16,539 16,539 16,539
Reference price 2 381.8 247.8 169.8 387.4 560.4 700.4
Announcement Date 7/2/18 7/6/19 7/28/20 8/7/21 7/7/22 7/13/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,440 3,302 3,756 3,891 4,402 5,128
EBITDA 1 376.5 332.6 563.1 683.5 846.2 1,020
EBIT 1 238.8 186.9 429.5 536.6 707.4 881
Operating Margin 6.94% 5.66% 11.44% 13.79% 16.07% 17.18%
Earnings before Tax (EBT) 1 203.6 150.5 364.5 535.8 731.7 916.8
Net income 1 134.5 108.1 290.1 400 514.8 676.4
Net margin 3.91% 3.27% 7.72% 10.28% 11.7% 13.19%
EPS 2 8.132 6.536 17.54 24.19 31.13 40.90
Free Cash Flow 1 -88.5 218 273.4 367.7 221.8 301.1
FCF margin -2.57% 6.6% 7.28% 9.45% 5.04% 5.87%
FCF Conversion (EBITDA) - 65.54% 48.55% 53.8% 26.21% 29.52%
FCF Conversion (Net income) - 201.64% 94.24% 91.93% 43.08% 44.51%
Dividend per Share 2 2.400 2.400 4.000 7.200 9.600 12.00
Announcement Date 7/2/18 7/6/19 7/28/20 8/7/21 7/7/22 7/13/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 541 361 112 - - -
Net Cash position 1 - - - 383 560 832
Leverage (Debt/EBITDA) 1.437 x 1.086 x 0.1985 x - - -
Free Cash Flow 1 -88.5 218 273 368 222 301
ROE (net income / shareholders' equity) 8.91% 6.86% 17.2% 20.4% 21.8% 24%
ROA (Net income/ Total Assets) 5.55% 4.31% 10.4% 11.8% 13.6% 14.4%
Assets 1 2,425 2,510 2,799 3,400 3,773 4,692
Book Value Per Share 2 93.60 97.00 107.0 131.0 155.0 186.0
Cash Flow per Share 2 0.0700 0.2200 0.3300 24.40 34.40 15.00
Capex 1 155 197 107 85.1 240 327
Capex / Sales 4.5% 5.96% 2.86% 2.19% 5.44% 6.38%
Announcement Date 7/2/18 7/6/19 7/28/20 8/7/21 7/7/22 7/13/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RPGLIFE Stock
  4. RPGLIFE Stock
  5. Financials RPG Life Sciences Limited